1 / 4

Leishmaniasis Treatment Market Upcoming Trends, Demand and Analysis Till 2026

Leishmaniasis is parasitic disease caused due to an infection with Leishmania parasites and transmitted through the bite of infected female phlebotomine sand flies.

rajbisen
Télécharger la présentation

Leishmaniasis Treatment Market Upcoming Trends, Demand and Analysis Till 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Leishmaniasis Treatment Leishmaniasis Treatment Market Size, Share, Trend, Outlook, Future Growth Analysis Trend, Outlook, Future Growth Analysis And Synthesis By 2026 And Synthesis By 2026 Market Size, Share, Leishmaniasis is parasitic disease caused due to an infection with Leishmania parasites and transmitted through the bite of infected female phlebotomine sand flies. According to the World Health Organization (WHO), approximately 7, 00,000 to 1 million new cases and 20,000 - 30,000 deaths occur worldwide annually due to the leishmaniasis. There are three forms of leishmaniasis namely mucocutaneous leishmaniasis, visceral leishmaniasis, and cutaneous leishmaniasis. Visceral leishmaniasis (VL) is the most serious condition among the other two forms of leishmaniasis. According to the World Health Organization (WHO), about 50,000 to 90,000 new cases of visceral leishmaniasis occur worldwide annually. Download PDF Brochure @ Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/932 https://www.coherentmarketinsights.com/insight/request-pdf/932 According to the WHO, in 2015, more than 90% of the new cases of visceral leishmaniasis were from Kenya, Somalia, Ethiopia, India, Brazil, Sudan, and South Sudan creating higher opportunity for leishmaniasis treatment market. The prevalence of cutaneous leishmaniasis in the North and South America, the Middle East, Central Asia, and Mediterranean basin is approximately 95%, according to the WHO April 2017 factsheet. People with leishmaniasis infection develop several symptoms, such as fever, weight loss, sores on skin, nose, mouth or throat, enlargement of spleen and liver, and abnormal blood tests. Some patients show symptoms of anemia, leukopenia, and thrombocytopenia. Geriatric population, infants, pregnant or lactating women, and HIV infected people have a high risk of acquiring leishmaniasis infections, due to their weak immune systems. Introduction of new chemical entity will drive the leishmaniasis treatment market Introduction of new chemical entity will drive the leishmaniasis treatment market According to data published in 2017, by Drugs for Neglected Diseases initiative (DNDi’), two new chemical entities (NCE) DNDI-6148 and DNDI-0690 are introduced into the preclinical development stage to treat visceral and cutaneous leishmaniasis in 2016. Immunomodulator- CpG-D35, is also in pre-clinical development stage, which will be used as an adjunct along with drug therapy to fight cutaneous leishmaniasis. These advances have the potential to transform drug development into new treatment therapy in near future, in turn driving the growth of leishmaniasis treatment market.

  2. Combined agreement between WHO and Gilead Sciences, Inc. will expand leishmaniasis treatment Combined agreement between WHO and Gilead Sciences, Inc. will expand leishmaniasis treatment market market In 2016, the World Health Organization (WHO) and Gilead Sciences, Inc. signed an agreement to donate 3,80,400 vials of AmBisome (liposomal amphotericin B), extending their previous agreement from 2016 to 2021. The five year collaboration and funding of US$ 20 million by Gilead Sciences, Inc. are intended to provide access to diagnosis and treatment to the populations affected by visceral leishmaniasis in key endemic countries such as Ethiopia, India, Nepal, Bangladesh, South Sudan, and Sudan. Financial contribution made by Gilead Sciences, Inc. helped WHO to expand, control, and reinforce surveillance in many endemic countries. Report includes chapters which deeply display the following deliverable about industry : Report includes chapters which deeply display the following deliverable about industry : • Leishmaniasis Treatment Market Research Objective and Assumption • Leishmaniasis Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Leishmaniasis Treatment Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Leishmaniasis Treatment Market, By Regions • Leishmaniasis Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Leishmaniasis Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Leishmaniasis Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Leishmaniasis Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion

  3. Key Players in the Leishmaniasis treatment market Key Players in the Leishmaniasis treatment market Key players operating in the leishmaniasis treatment market include Sanofi S.A., Sequus Pharmaceuticals Inc., Paladin Labs Inc., Enzon Pharmaceuticals Inc., Gland Pharma Limited, and Lifecare Innovations Private Limited. Leishmaniasis Treatment Market Taxonomy: Leishmaniasis Treatment Market Taxonomy: On the basis of disease type, the leishmaniasis treatment market is segmented into: On the basis of disease type, the leishmaniasis treatment market is segmented into: Cutaneous leishmaniasis • Visceral leishmaniasis • Mucocutaneous leishmaniasis • On the basis of drug type, the leishmaniasis treatment market is segmented into: On the basis of drug type, the leishmaniasis treatment market is segmented into: - Pentavalent antimonials Sodium stibogluconate • SSG Meglumine antimoniate • - Antibiotics Amphotericin B • Liposomal amphotericin B • Miltefosine • Paromomycin • Pentamidine • Browse In-Depth Analysis Research Report @ Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoing- https://www.coherentmarketinsights.com/ongoing- insight/leishmaniasis-treatment-market-932 insight/leishmaniasis-treatment-market-932

  4. About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: Email: sales@coherentmarketinsights.com sales@coherentmarketinsights.com

More Related